Journal of Clinical Immunology

, Volume 28, Issue 3, pp 276–283 | Cite as

Modified Donor Lymphocyte Infusion after HLA-Mismatched/Haploidentical T Cell-replete Hematopoietic Stem Cell Transplantation for Prophylaxis of Relapse of Leukemia in Patients with Advanced Leukemia

  • Xiao-Jun Huang
  • Dai-Hong Liu
  • Kai-Yan Liu
  • Lan-Ping Xu
  • Yu-Hong Chen
  • Yu Wang
  • Wei Han
  • Huan Chen


We evaluated the safety and efficacy of donor lymphocyte infusion (DLI) with granulocyte colony-stimulating factor priming and short-term immunosuppressive agents for prophylaxis of relapse in patients with advanced leukemia after human leukocyte antigen (HLA)-mismatched T cell-replete hematopoietic stem cell transplantation (HCT). Twenty-nine patients received prophylactic DLI at a median 75 (33–120) days after HCT. Acute graft-vs-host disease (GVHD) grades 3–4 occurred in six patients, and all cases were controlled. Eleven patients were alive and relapse-free with a probability of leukemia-free survival (LFS) of 37.3 ± 9.6% at 3 years. Chronic GVHD was associated with a lower relapse rate and higher probability of LFS. Prophylactic-modified DLI is feasible in patients with advanced leukemia to prevent relapse after HLA-mismatched HCT.


Donor lymphocyte infusion HLA-mismatched transplantation haploidentical HSCT GVHD relapse DLI 



This work is supported by the National Outstanding Young Scientist’s Foundation of China (grant no. 30725038), Hi-tech Research and Development Program of China (no. 2006AA02Z4A0), and Program for Innovative Research Team in the University (No. IRT0702).


  1. 1.
    Robak T, Wrzesien-Kus A. The search for optimal treatment in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma 2002;43:281–91.PubMedCrossRefGoogle Scholar
  2. 2.
    Michallet M, Thomas X, Vernant JP, et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplant 2000;26:1157–63.PubMedCrossRefGoogle Scholar
  3. 3.
    Slavin S, Naparstek E, Nagler A. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996;87:2195–204.PubMedGoogle Scholar
  4. 4.
    Huang XJ, Guo NL, Ren HY, Xu LP, Chen H, Liu KY, et al. An improved anti-leukemic effect achieved with donor progenitor cell infusion for relapse patients after allogeneic bone marrow transplantation. Chinese Med J 2003;116:736–41.Google Scholar
  5. 5.
    Huang XJ, Liu DH, Xu LP, Chen H, Liu KY, Han W, et al. Prophylactic infusion of donor granulocyte colony stimulating factor mobilized peripheral blood progenitor cells after allogeneic hematological stem cell transplantation in patients with high-risk leukemia. Leukemia 2006;20:365–8.PubMedCrossRefGoogle Scholar
  6. 6.
    De Lima M, Bonamino M, Vasconcelos Z, et al. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease. Bone Marrow Transplant 2001;27:73–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007;92:414–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Mengarelli A, Iori A, Guglielmi C, et al. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Haematologica 2002;87:52–8.PubMedGoogle Scholar
  9. 9.
    Appelbaum FR. Who should be transplanted for AML. Leukemia 2001;15:680–2.PubMedCrossRefGoogle Scholar
  10. 10.
    Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006;38:291–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Liu Y, Chen S, Yu H. Standardization and quality control in flow cytometric enumeration of CD34(+) cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2000;8:302–6.PubMedGoogle Scholar
  12. 12.
    Flower ME, Kansu E, Sullivan KM. Pathophysiology and treatment of graft-versus-host disase. Hematol Oncol Clin North Am 1999;13:1091–112.CrossRefGoogle Scholar
  13. 13.
    Keith MS. Graft-vs.-host disease. In: Thomas ED, Blume KG, Forman SJ, Appelbaum FR, editors. Thomas’ hematopoietic cell transplantation. 3rd ed. Malden, MA: Blackwell; 2004. p. 635–64.Google Scholar
  14. 14.
    Singhal S, Powles R, Henslee-Downey PJ, et al. Allogeneic transplantation from HLA-matched sibling or partially HLA-mismatched related donors for primary refractory acute leukemia. Bone Marrow Transplant 2002;29:291–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075–83.PubMedGoogle Scholar
  16. 16.
    Estey EH. Treatment of relapsed and refractory acute myeloid leukemia. Leukemia 2000;14:476–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol 1992;10:1723–9.PubMedGoogle Scholar
  18. 18.
    Christoph S, Michael S, Rainer S, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006;108:1092–9.CrossRefGoogle Scholar
  19. 19.
    Alessandrino EP, Bernasconi P, Caldera D. Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999;23:607–12.PubMedCrossRefGoogle Scholar
  20. 20.
    Chen SH, Li X, Huang XJ. Effect of recombinant human granulocyte colony-stimulating factor on T-lymphocyte function and the mechanism of this effect. Int J Hematol 2004;79:178–84.PubMedCrossRefGoogle Scholar
  21. 21.
    Huang XJ, Chang YJ, Zhao XY. In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Haematologica 2004;89:1517–24.Google Scholar
  22. 22.
    Huang XJ, Chang YJ, Zhao XY. A direct comparison of immunological characteristics of granulocyte colony-stimulating factor (G-CSF)-primed bone marrow grafts and G-CSF-mobilized peripheral blood grafts. Haematologica 2005;90:715–6.Google Scholar
  23. 23.
    Huang XJ, Chang YJ, Zhao XY. Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. Transplant Immunol 2007;17:193–7.CrossRefGoogle Scholar
  24. 24.
    Sohn SK, Jung JT, Kim DH, Lee NY, Seo KW, Chae YS, et al. Prophylactic growth factor-mobilized donor lymphocyte infusion using cells reserved at the time of transplantation after allogeneic peripheral blood stem cell transplantation in patients with high-risk hematologic malignancies. Cancer 2002;94:18–24.PubMedCrossRefGoogle Scholar
  25. 25.
    Yanada M, Naoe T, Iida H. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease. Bone Marrow Transplant 2005;36:867–72.PubMedCrossRefGoogle Scholar
  26. 26.
    Ko BS, Tang JL, Tsai W. Philadelphia chromosome-positive acute lymphoblastic leukemia in Taiwan. Ann Hematol 2001;80:510–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Xiao-Jun Huang
    • 1
  • Dai-Hong Liu
    • 1
  • Kai-Yan Liu
    • 1
  • Lan-Ping Xu
    • 1
  • Yu-Hong Chen
    • 1
  • Yu Wang
    • 1
  • Wei Han
    • 1
  • Huan Chen
    • 1
  1. 1.Institute of HematologyPeople’s Hospital, Peking UniversityBeijingPeople’s Republic of China

Personalised recommendations